ID

26682

Descripción

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Standard of care medications

Palabras clave

Versiones (3)
  1. 27/8/17 27/8/17 -
  2. 23/10/17 23/10/17 -
  3. 12/12/17 12/12/17 -
Titular de derechos de autor

GlaxoSmithKline

Subido en

23 de octubre de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Standard of care medications GSK study Chronic Coronary Heart Disease NCT00799903

Inglés

Standard of care medications GSK study Chronic Coronary Heart Disease NCT00799903

1 formularios  
Standard of care medications
Descripción

Standard of care medications

1. Was the subject regularly taking STATIN therapy for 8 weeks or more prior to randomisation?
Descripción

STATIN therapy prior to randomisation

Tipo de datos

boolean

2. Was the subject taking STATIN therapy at the time of randomisation?
Descripción

STATIN therapy at randomisation

Tipo de datos

boolean

If no, indicate reason
Descripción

no STATIN therapy at randomisation reason

Tipo de datos

text

If other reason, specify:
Descripción

no STATIN therapy at randomisation other reason

Tipo de datos

text

3. Was the subject regularly taking ASPIRIN therapy for 8 weeks or more prior to randomisation?
Descripción

ASPIRIN therapy prior to randomisation

Tipo de datos

boolean

4. Was the subject taking ASPIRIN at the time of randomisation?
Descripción

ASPIRIN at randomisation

Tipo de datos

boolean

If no, indicate reason:
Descripción

no ASPIRIN at randomisation reason

Tipo de datos

text

If other reason, specify:
Descripción

no ASPIRIN at randomisation other reason

Tipo de datos

text

5. Is the subject regularly taking any P2Y12 inhibitors (i.e. thienopyridines)?
Descripción

P2Y12 inhibitors

Tipo de datos

boolean

If no, indicate reason:
Descripción

no P2Y12 inhibitors reason

Tipo de datos

text

If other reason, specify:
Descripción

no P2Y12 inhibitors other reason

Tipo de datos

text

6. Is the subject taking a beta-blocker?
Descripción

beta-blocker

Tipo de datos

boolean

If no, indicate reason:
Descripción

no beta-blocker reason

Tipo de datos

text

If other reason, specify:
Descripción

no beta-blocker other reason

Tipo de datos

text

7. Is the subject taking an ACE inhibitor?
Descripción

ACE inhibitor

Tipo de datos

boolean

If no, indicate reason:
Descripción

no ACE inhibitor reason

Tipo de datos

text

If other reason, specify:
Descripción

no ACE inhibitors other reason

Tipo de datos

text

8. Is the subject taking an ARB?
Descripción

ARB

Tipo de datos

boolean

If no, indicate reason:
Descripción

no ARB reason

Tipo de datos

text

If other reason, specify:
Descripción

no ARB other reason

Tipo de datos

text

9. Is the subject taking any other renin-angiotensin-aldosterone system-targeted medication?
Descripción

renin-angiotensin-aldosterone system-targeted medication

Tipo de datos

boolean

If no, indicate reason:
Descripción

no renin-angiotensin-aldosterone system-targeted medication reason

Tipo de datos

text

If other reason, specify:
Descripción

no renin-angiotensin-aldosterone system-targeted medication other reason

Tipo de datos

text

Volver a la parte superior de la página

Similar models

Standard of care medications GSK study Chronic Coronary Heart Disease NCT00799903

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Standard of care medications
STATIN therapy prior to randomisation
Item
1. Was the subject regularly taking STATIN therapy for 8 weeks or more prior to randomisation?
boolean
STATIN therapy at randomisation
Item
2. Was the subject taking STATIN therapy at the time of randomisation?
boolean
Item
If no, indicate reason
text
no STATIN therapy at randomisation reason
Code List
If no, indicate reason
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
Item
If other reason, specify:
text
no STATIN therapy at randomisation reason
Code List
If other reason, specify:
ASPIRIN therapy prior to randomisation
Item
3. Was the subject regularly taking ASPIRIN therapy for 8 weeks or more prior to randomisation?
boolean
ASPIRIN at randomisation
Item
4. Was the subject taking ASPIRIN at the time of randomisation?
boolean
Item
If no, indicate reason:
text
no STATIN therapy at randomisation reason
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
no ASPIRIN at randomisation other reason
Item
If other reason, specify:
text
P2Y12 inhibitors
Item
5. Is the subject regularly taking any P2Y12 inhibitors (i.e. thienopyridines)?
boolean
Item
If no, indicate reason:
text
no STATIN therapy at randomisation reason
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no P2Y12 inhibitors other reason
Item
If other reason, specify:
text
beta-blocker
Item
6. Is the subject taking a beta-blocker?
boolean
Item
If no, indicate reason:
text
no STATIN therapy at randomisation reason
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no beta-blocker other reason
Item
If other reason, specify:
text
ACE inhibitor
Item
7. Is the subject taking an ACE inhibitor?
boolean
Item
If no, indicate reason:
text
no STATIN therapy at randomisation reason
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no ACE inhibitors other reason
Item
If other reason, specify:
text
ARB
Item
8. Is the subject taking an ARB?
boolean
Item
If no, indicate reason:
text
no STATIN therapy at randomisation reason
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no ARB other reason
Item
If other reason, specify:
text
renin-angiotensin-aldosterone system-targeted medication
Item
9. Is the subject taking any other renin-angiotensin-aldosterone system-targeted medication?
boolean
no STATIN therapy at randomisation reason
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no renin-angiotensin-aldosterone system-targeted medication other reason
Item
If other reason, specify:
text
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial